Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Emoxypine succinate (Mexidol) and L-Tetrahydropalmatine (L-THP) — mechanism, side effects, legal status, and pricing.
Emoxypine succinate (Mexidol) is a non-peptide small-molecule 3-hydroxypyridine derivative, the succinate salt of 2-ethyl-6-methyl-3-hydroxypyridine. It is a registered prescription drug in Russia and CIS states since the 1990s (IV/IM solution and oral tablet forms) but is NOT approved by the FDA or EMA. In the US and EU, it is sold only as an unregulated research chemical by nootropic vendors, typically labeled "not for human consumption." A 2024 peer-reviewed analysis flags its antihypoxic/metabolic-modulator profile as pharmacologically similar to WADA-banned agents meldonium and trimetazidine, documents past use by Russian athletes, and identifies it as a candidate for future prohibited-list consideration—though it is not currently WADA-prohibited.
L-Tetrahydropalmatine (L-THP) is a non-peptide isoquinoline alkaloid naturally occurring in Corydalis yanhusuo and Stephania rotunda. It acts as a mixed dopamine receptor antagonist with affinity for D1, D2, D3, serotonin 5-HT1A, and alpha-1 adrenergic receptors, and facilitates GABA-A receptor binding. One randomized controlled trial in schizophrenia found no efficacy on psychiatric symptoms and unexpectedly raised inflammatory markers. Widely sold by gray-market vendors as a research chemical labeled “not for human consumption.”
Emoxypine succinate (Mexidol)
L-Tetrahydropalmatine (L-THP)
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Emoxypine succinate (Mexidol)
No pricing data yet.
Check Emoxypine succinate (Mexidol) prices →L-Tetrahydropalmatine (L-THP)
No pricing data yet.
Check L-Tetrahydropalmatine (L-THP) prices →COA corpus from Disclosed Labs — independently tested batches only.
Emoxypine succinate (Mexidol)
1
COAs
99.9%
Avg purity
1
Labs
L-Tetrahydropalmatine (L-THP)
2
COAs
99.1%
Avg purity
2
Labs
Human data: Registered/marketed prescription drug in Russia and CIS states since the 1990s; multiple Russia-conducted trials exist, including a published multicenter double-blind placebo-controlled RCT (MEGA) in 333 children aged 6–12 with ADHD across 14 Russian centers using 125 mg tablets. No FDA/EMA-reviewed pivotal trial or US-marketed product exists; independent non-Russian-sponsored replication is limited. Preclinical: In rats (180–240 g), 6.25–25 mg/kg emoxypine reduced forced-swim-test immobility by ~24% and orientational activity by ~53% (antidepressant-like activity, animal data only). In isolated/anesthetized rat hearts, 10 mg/kg IV increased collateral coronary blood flow without altering systemic blood pressure (animal data only). In vitro (Caco-2/HEK293-SLCO1B1/HepG2 cell lines), the compound inhibited ABCB1 and SLCO1B1 transporters less potently than reference inhibitors; authors judged systemic effect not clinically significant.
Key references
One completed randomized, double-blind, placebo-controlled trial (NCT02118610; 63 adults with schizophrenia, 60 mg/day L-THP vs placebo for 4 weeks) found no significant benefit on positive, negative, depressive, or global symptom measures. The trial did show reduced extrapyramidal symptoms (p<.001, possibly confounded by anticholinergic co-medication) but unexpectedly raised inflammatory markers (sICAM-1 p=.004, CRP p=.039) rather than lowering them as animal data had suggested. Preclinical studies in rats demonstrated dose-dependent reductions in methamphetamine self-administration and reinstatement (1.25–5.0 mg/kg IP), reduced cocaine self-administration breaking points and discrimination (1.875–7.5 mg/kg), and decreased voluntary ethanol drinking in mice (10 mg/kg) via D2-receptor-mediated PKA signaling in dorsal striatum, without affecting locomotor activity at lower doses.
Emoxypine succinate (Mexidol) and L-Tetrahydropalmatine (L-THP) are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs